Strategic Alliances Hansoh has a track record of high-value licensing and strategic partnerships with global players (GSK, Roche, Regeneron, Merck) and intent to expand via collaborations, suggesting strong potential for co-development, exclusive licenses, or distribution deals in oncology, autoimmune, and metabolic spaces.

Growth Momentum Multiple recent deals and strategic investments indicate a growth-focused expansion trajectory, offering opportunities to engage in joint ventures, in-licensing of late-stage candidates, or regional market expansion initiatives.

Pipeline Leverage Hansoh’s active portfolio across oncology, antibiotics, psychotropic, antidiabetics, GI, and cardiovascular areas, plus late-stage GLP-1/GIP programs and ADCs, creates avenues for targeted BD pitches in high-value therapeutic areas.

Global Access With licensing outside China for programs like GLP-1/GIP and collaboration with Merck and Regeneron, there is clear receptivity to international partnerships; target distributors, CROs, and regional licensors to unlock cross-border sales and manufacturing opportunities.

Manufacturing know-how Hansoh emphasizes lean manufacturing and advanced tech (automation, robotics, PLM-like tools), suggesting opportunities for contract manufacturing, technology transfer, or co-investments to scale production for in-demand therapies.